Novo Nordisk's (NYSE: NVO) shares have dropped significantly over the past year, partly due to clinical setbacks in its core GLP-1 portfolio. However, the Denmark-based pharmaceutical leader has been ...
Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...
Hosted on MSN
How safe is Pfizer's dividend as 2026 begins?
Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...
WASHINGTON — A key Republican senator on health issues and the CEO of Pfizer said the effort known as Operation Warp Speed under President Donald Trump to rapidly create and disseminate COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results